Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 4/2010

01-07-2010

Is There a Role for Antiplatelet Therapy in Infective Endocarditis? A Review of Current Scientific Evidence

Authors: Nandan S. Anavekar, Joseph G. Murphy

Published in: Current Infectious Disease Reports | Issue 4/2010

Login to get access

Abstract

Recently, interest has emerged regarding adjuvant antiplatelet therapy in infective endocarditis (IE) and its impact on clinical outcomes. Despite ongoing research, the role of antiplatelet therapy in this setting remains unclear. Generally, investigations of IE are limited by the low incidence of the disease, practical issues related to diagnosis, and the highly variable latency period between symptom onset and definitive diagnosis. This article reviews the rationale for using antiplatelet therapy in the setting of IE and the contemporary literature that investigates its use.
Literature
1.
Steckelberg JM, Murphy JG, Ballard D, et al.: Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991, 114:635–640.PubMed
2.
• Tleyjeh IM, Steckelberg JM, Murad HS, et al.: Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA 2005, 293:3022–3028. This article delineates the epidemiology of IE in a homogenous populations, providing validity of outcome measures.CrossRefPubMed
3.
Baddour LM, Wilson WR, Baye AS, et al.: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394–e434.CrossRefPubMed
4.
Delahaye JP, Poncet P, Malquarti V, et al.: Cerebrovascular accidents in infective endocarditis: role of anticoagulation. Eur Heart J 1990, 11:1074–1078.PubMed
5.
Heiro M, Nikoskelainen J, Engblom E, et al.: Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med 2000, 160:2781–2787.CrossRefPubMed
6.
Sanfilippo AJ, Picard MH, Newell JB, et al.: Echocardiographic assessment of patients with infectious endocarditis: prediction of risk for complications. J Am Coll Cardiol 1991, 18:1191–1199.CrossRefPubMed
7.
• Anavekar NS, Tleyjeh IM, Anavekar NS, et al.: Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis 2007, 44:1180–1186. This article is a retrospective study that demonstrates a benefit of prior antiplatelet therapy on outcomes in patients with infective endocarditis.CrossRefPubMed
8.
Chan KL, Dumesnil JG, Cujec B, et al.: A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 2003, 42:775–780.CrossRefPubMed
9.
• Chan KL, Tam J, Dumesnil JG, et al.: Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis 2008, 46:37–41. This article describes the only major randomized controlled trial in infective endocarditis that was designed to assess utility of aspirin therapy.CrossRefPubMed
10.
• Sedlacek M, Gemery JM, Cheung AL, et al.: Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am J Kidney Dis 2007, 49:401–408. This article provides clinical evidence for antimicrobial activity of aspirin in the setting of S. aureus bacteremia.CrossRefPubMed
11.
Kupferwasser LI, Yeaman MR, Nast CC, et al.: Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 2003, 112:222–233.PubMed
12.
Kupferwasser LI, Yeaman MR, Shapiro SM, et al.: Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999, 99:2791–2797.PubMed
13.
Nicolau DP, Freeman CD, Nightingale CH, et al.: Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun 1993, 61:1593–1595.PubMed
14.
Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R: Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1995, 39:1748–1751.PubMed
15.
Nicolau DP, Tessier PR, Nightingale CH: Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1999, 11:159–161.CrossRefPubMed
16.
Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R: Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1998, 9:227–229.CrossRefPubMed
17.
Durack DT, Beeson PB: Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol 1972, 53:44–49.PubMed
18.
Domenico P, Schwartz S, Cunha BA: Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 1989, 57:3778–3782.PubMed
19.
Farber BF, Wolff AG: The use of nonsteroidal antiinflammatory drugs to prevent adherence of Staphylococcus epidermidis to medical polymers. J Infect Dis 1992, 166:861–865.PubMed
20.
Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191–1195.CrossRefPubMed
21.
Polonio RE, Mermel LA, Paquette GE, Sperry JF: Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin. Antimicrob Agents Chemother 2001, 45:3262–3266.CrossRefPubMed
22.
Taha TH, Durrant SS, Mazeika PK, et al.: Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med 1992, 231:543–546.CrossRefPubMed
23.
Eisen DP, Corey GR, McBryde ES, et al.: Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect 2009, 58:332–338.CrossRefPubMed
24.
Kessler M, Hoen B, Mayeux D, et al.: Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993, 64:95–100.CrossRefPubMed
Metadata
Title
Is There a Role for Antiplatelet Therapy in Infective Endocarditis? A Review of Current Scientific Evidence
Authors
Nandan S. Anavekar
Joseph G. Murphy
Publication date
01-07-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 4/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0115-2

Other articles of this Issue 4/2010

Current Infectious Disease Reports 4/2010 Go to the issue

ReviewPaper

Clinical and Microbiologic Features of Multivalvular Endocarditis

Clinical Trial Report

Clinical Trial Report: Is It Safe to Continue Anticoagulation Therapy in Patients with Infective Endocarditis?

ReviewPaper

Molecular Methods for Diagnosis of Infective Endocarditis

ReviewPaper

Cryptococcal Meningitis: Current Approaches to Management in Patients With and Without AIDS

ReviewPaper

Approach to the Diagnosis and Management of Tuberculous Meningitis

ReviewPaper

Mycoplasma genitalium: Is It a Sexually Transmitted Pathogen?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits